Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | RAD51C |
| Variant | H192_R193delinsGG |
| Impact List | indel |
| Protein Effect | no effect |
| Gene Variant Descriptions | RAD51C H192_R193delinsGG results in a deletion of two amino acids in the Rad51c protein combined with the insertion of two new amino acids in the same location (UniProt.org). H192_R193delinsGG, described as a reversion mutation, has no effect on Rad51c protein function, as demonstrated by restoration of homologous recombination function similar to wild-type Rad51c in cultured cells, and is associated with acquired resistance to PARP inhibitors (PMID: 28588062). |
| Associated Drug Resistance | Y |
| Category Variants Paths |
RAD51C mutant RAD51C H192_R193delinsGG |
| Transcript | NM_058216.3 |
| gDNA | chr17:g.58703198_58703203delinsGGTGGT |
| cDNA | c.574_579delinsGGTGGT |
| Protein | p.H192_R193delinsGG |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_058216 | chr17:g.58703198_58703203delinsGGTGGT | c.574_579delinsGGTGGT | p.H192_R193delinsGG | RefSeq | GRCh38/hg38 |
| XM_006722001 | chr17:g.58703198_58703203delinsGGTGGT | c.574_579delinsGGTGGT | p.H192_R193delinsGG | RefSeq | GRCh38/hg38 |
| XM_006722001.4 | chr17:g.58703198_58703203delinsGGTGGT | c.574_579delinsGGTGGT | p.H192_R193delinsGG | RefSeq | GRCh38/hg38 |
| XM_047436505.1 | chr17:g.58703198_58703203delinsGGTGGT | c.574_579delinsGGTGGT | p.H192_R193delinsGG | RefSeq | GRCh38/hg38 |
| XM_006722002.4 | chr17:g.58703198_58703203delinsGGTGGT | c.574_579delinsGGTGGT | p.H192_R193delinsGG | RefSeq | GRCh38/hg38 |
| XM_006722002.5 | chr17:g.58703198_58703203delinsGGTGGT | c.574_579delinsGGTGGT | p.H192_R193delinsGG | RefSeq | GRCh38/hg38 |
| XM_006722001.5 | chr17:g.58703198_58703203delinsGGTGGT | c.574_579delinsGGTGGT | p.H192_R193delinsGG | RefSeq | GRCh38/hg38 |
| XM_006722002 | chr17:g.58703198_58703203delinsGGTGGT | c.574_579delinsGGTGGT | p.H192_R193delinsGG | RefSeq | GRCh38/hg38 |
| NM_058216.2 | chr17:g.58703198_58703203delinsGGTGGT | c.574_579delinsGGTGGT | p.H192_R193delinsGG | RefSeq | GRCh38/hg38 |
| NM_058216.3 | chr17:g.58703198_58703203delinsGGTGGT | c.574_579delinsGGTGGT | p.H192_R193delinsGG | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| RAD51C H192_R193delinsGG | ovarian carcinoma | resistant | Rucaparib | Preclinical - Cell culture | Actionable | In a preclinical study, ovarian carcinoma cells expressing RAD51C H192_R193delinsGG demonstrated resistance to Rubraca (rucaparib) in culture (PMID: 28588062). | 28588062 |
| RAD51C H192_R193delinsGG | ovarian carcinoma | resistant | Niraparib | Preclinical - Cell culture | Actionable | In a preclinical study, ovarian carcinoma cells expressing RAD51C H192_R193delinsGG demonstrated resistance to Zejula (niraparib) in culture (PMID: 28588062). | 28588062 |
| RAD51C H192_R193delinsGG | ovarian carcinoma | resistant | Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, ovarian carcinoma cells expressing RAD51C H192_R193delinsGG demonstrated resistance to Lynparza (olaparib) in culture (PMID: 28588062). | 28588062 |
| RAD51C H192_R193delinsGG | ovarian carcinoma | resistant | Talazoparib | Preclinical - Cell culture | Actionable | In a preclinical study, ovarian carcinoma cells expressing RAD51C H192_R193delinsGG demonstrated resistance to Talzenna (talazoparib) in culture (PMID: 28588062). | 28588062 |
| RAD51C H192_R193delinsGG | ovarian carcinoma | resistant | Veliparib | Preclinical - Cell culture | Actionable | In a preclinical study, ovarian carcinoma cells expressing RAD51C H192_R193delinsGG demonstrated resistance to Veliparib (ABT-888) in culture (PMID: 28588062). | 28588062 |